Insider Transactions in Q2 2023 at Satsuma Pharmaceuticals, Inc. (STSA)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 08
2023
|
Ra Capital Management, L.P. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,914,252
-100.0%
|
-
|
|
Jun 08
2023
|
Shin Nippon Biomedical Laboratories, Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,423,732
+50.0%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
Rajeev M. Shah Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,914,252
-100.0%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
Thomas P. O'Neil Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
13,877
-100.0%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
Ken Takanashi Director |
BUY
Open market or private purchase
|
Indirect |
22,053,581
+47.02%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
John A Kollins President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
305,911
-100.0%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
Shin Nippon Biomedical Laboratories, Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,053,581
+50.0%
|
$0
$0.91 P/Share
|